State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Department and Institute of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095, Jiefang Avenue, Wuhan, 430030, P.R. China.
Department of Infectious Disease, Center for Liver Disease, Peking University First Hospital, Beijing, China.
Hepatol Int. 2024 Jun;18(3):817-832. doi: 10.1007/s12072-023-10637-3. Epub 2024 Mar 9.
End-stage liver disease (ESLD) is a life-threatening clinical syndrome and when complicated with infection the mortality is markedly increased. In patients with ESLD, bacterial or fungal infection can induce or aggravate the occurrence or progression of liver decompensation. Consequently, infections are among the most common complications of disease deterioration. There is an overwhelming need for standardized protocols for early diagnosis and appropriate management for patients with ESLD complicated by infections. Asia Pacific region has the largest number of ESLD patients, due to hepatitis B and the growing population of alcohol and NAFLD. Concomitant infections not only add to organ failure and high mortality but also to financial and healthcare burdens. This consensus document assembled up-to-date knowledge and experience from colleagues across the Asia-Pacific region, providing data on the principles as well as evidence-based current working protocols and practices for the diagnosis and treatment of patients with ESLD complicated by infections.
终末期肝病(ESLD)是一种危及生命的临床综合征,当合并感染时,死亡率显著增加。在 ESLD 患者中,细菌或真菌感染可诱发或加重肝功能失代偿的发生或进展。因此,感染是疾病恶化最常见的并发症之一。对于 ESLD 合并感染的患者,迫切需要制定标准化的早期诊断和适当管理的方案。亚太地区由于乙型肝炎和酒精性肝病及非酒精性脂肪性肝病患者人数的增加,ESLD 患者数量最多。合并感染不仅会导致器官衰竭和高死亡率,还会增加经济和医疗负担。这份共识文件汇集了来自亚太地区同事们的最新知识和经验,提供了关于原则以及基于证据的当前诊断和治疗 ESLD 合并感染患者的工作方案和实践的数据。